COMMUNIQUÉS West-GlobeNewswire

Immuron Letter to Shareholders – Projects Update
02/10/2025
Highlights: US Tariffs: Immuron does not anticipate any material impact from the recently announced US tariffs on pharmaceutical products Travelan ® Clinical Study: Topline results from the Travelan ® clinical study [...]
Pennant Completes Purchase of Tennessee, Georgia and Alabama Operations from UnitedHealth Group and Amedisys
02/10/2025
EAGLE, Idaho, Oct. 02, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, announced today [...]
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium
02/10/2025
STAFFORD, Texas, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
AM-Pharma Completes Enrollment in Phase 2 Study of Ilofotase Alfa for Prevention of Cardiac Surgery-Associated Renal Damage
02/10/2025
Utrecht, The Netherlands, October 2, 2025 – AM-Pharma B.V. today announced that it has successfully completed enrollment of patients in its ongoing Phase 2 clinical trial evaluating ilofotase alfa for the prevention of [...]
Precision Neuroscience Reports First High-Bandwidth Brain–Computer Interface Achieved Without Open Surgery
02/10/2025
Study in Nature Biomedical Engineering details Precision’s surface-based system and shows results from the first five patients NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision), [...]
Igyxos Biotherapeutics Awarded EUR 5.7 Million from the French Government to Accelerate Development of its First-in-class Monoclonal Antibody for the Treatment of Infertility
02/10/2025
TOURS, France, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Igyxos Biotherapeutics, a biotechnology company dedicated to developing innovative monoclonal antibodies for infertility treatment, today announced that it has secured a [...]
Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations
02/10/2025
Press Release Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations Additional pre-planned analysis of the NCX 470 Denali trial completed NCX 470 [...]
Nicox annonce que NCX 470 a démontré une efficacité soutenue jusqu’à 12 mois dans l’essai clinique Denali, sans effets indésirables nouveaux observés
02/10/2025
Communiqué de presse Nicox annonce que NCX 470 a démontré une efficacité soutenue jusqu’à 12 mois dans l’essai clinique Denali, sans effets indésirables nouveaux observés Les analyses additionnelles préplanifiées de l’ [...]
e-therapeutics relance son activité sous le nom de Tangram Therapeutics et présente LLibra OS
02/10/2025
Ce renouveau marque une étape décisive dans la croissance de la Société, qui prévoit de soumettre sa première demande d’essai clinique (ou CTA, de l’anglais « Clinical Trial Application ») au quatrième trimestre 2025. [...]
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025
02/10/2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of [...]
New Imprivata Report Finds that Australian Hospitals Save More Than $1.2 Million AUD Annually with Shared-Use Mobile Devices, but Strategic Gaps Still Pose Security and Operational Risk
02/10/2025
The 2025 Imprivata State of Shared Mobile Devices in Healthcare Report identifies the benefits as well as the challenges Australian healthcare organisations face when implementing shared-use mobile devices for clinical [...]
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/10/2025
SAN DIEGO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for [...]
Roche commences tender offer for all shares of 89bio, Inc. for $14.50 per share in cash, plus a non-tradeable contingent value right for up to $6.00 per share in cash
01/10/2025
Basel, 1 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has commenced a tender offer for all of the outstanding shares of common stock of 89bio, Inc. (89bio) (NASDAQ: ETNB) at a price of $14. [...]
TOMI Environmental Solutions Appoints Harold W. Paul to Its Board of Directors
01/10/2025
- Brings Over 40 years of Legal, Securities, and Board Leadership Experience Across Multiple Industries - FREDERICK, Md., Oct. 01, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a [...]
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine
01/10/2025
Maetzold recognized among 586 applicants to The CEO Magazine’s 2025 Executive of the Year Awards — United States program FRIENDSWOOD, Texas, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a [...]
Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
01/10/2025
SARASOTA, FL, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery [...]
NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer
01/10/2025
Treatment was well-tolerated and injection feasibility was confirmed in 13 patients with locally advanced adenocarcinoma of the esophagus 85% (11/13) disease control rate (DCR) 69% (9/13) objective response rate (ORR); [...]
NANOBIOTIX annonce les premières données de Phase 1 évaluant JNJ-1900 (NBTXR3) chez des patients atteints de cancer de l’œsophage
01/10/2025
Le traitement a été bien toléré et la faisabilité de l’injection a été confirmée chez les 13 patients atteints d’adénocarcinome de l’œsophage localement avancé. Le taux de contrôle de la maladie (DCR, disease control [...]
Vital Nutrients Expands Clinical Line With New Formula for Women’s Hair Health
01/10/2025
MIDDLETOWN, Conn., Oct. 01, 2025 (GLOBE NEWSWIRE) -- With female hair loss on the rise, Vital Nutrients is introducing Hair Growth Complex for Women , a clinically formulated supplement targeting the biological drivers [...]

Pages